---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-117257"
form_type: "8-K"
ticker: "ELUT"
cik: "0001708527"
company_name: "ELUTIA INC."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:16:26.507491+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Elutia Q3 net sales $6.1M (+5% YoY); proprietary products up 26%; narrows net loss; to file 510(k) for CanGarooRM in Q4

## Summary
- Net loss from continuing ops $8.5M ($0.50/sh), improving from $11.0M ($0.81/sh) YoY.
- Proprietary product sales (SimpliDerm +44%, CanGaroo +11% YoY) drove 26% overall proprietary growth; total net sales $6.1M.
- Completed Orthobiologics divestiture for initial $15M, plus private placement netting $10.5M; cash balance $14.5M at Sept 30.
- Anticipates FDA 510(k) filing for CanGarooRM by year-end 2023, targeting $600M drug-eluting CIED envelope market.
- Operating expenses down 14% YoY to $10.2M; gross margin declined to 46.4% from 50.2% due to distributor pricing shift.

## SEC filing metadata
- accession: 0001104659-23-117257
- form_type: 8-K
- ticker: ELUT
- cik: 0001708527
- company_name: ELUTIA INC.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708527/000110465923117257/0001104659-23-117257-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708527/000110465923117257/tm2330559d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-117257
- JSON: https://secwatch.observer/filing/0001104659-23-117257.json
- Plain text: https://secwatch.observer/filing/0001104659-23-117257.txt

## Key facts
- Earnings Releases
  ELUTIA INC. reported third quarter ended September 30, 2023 results: revenue $6.1 million, net income $8.5 million, EPS $0.50 per share.
  - Period: third quarter ended September 30, 2023
  - Revenue: $6.1 million
  - Net income: $8.5 million
  - EPS: $0.50 per share
  - Result: reported results
  source text: and minocycline, we believe CanGarooRM is well-positioned to compete effectively in this space. Third Quarter 2023 Financial Results Net sales for the third quarter of 2023 were $6.1 million, compared to $5.8 million in the third quarter of 2022. Net sales of both SimpliDerm and CanGaroo performed well, growing 44% and 11%, respectively, versus the third quarter of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708527/000110465923117257/0001104659-23-117257-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.